{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:48:11Z","timestamp":1792795691484,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jagp.2019.09.009","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T18:53:52Z","timestamp":1569956032000},"page":"383-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"title":["Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials"],"prefix":"10.1016","volume":"28","author":[{"given":"George T.","family":"Grossberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kohegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Mergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Krog","family":"Josiassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Meulien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hobart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Slomkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jagp.2019.09.009_bib0001","series-title":"World Alzheimer Report 2015. The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends","author":"Prince","year":"2015"},{"key":"10.1016\/j.jagp.2019.09.009_bib0002","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","article-title":"2018 Alzheimer's disease facts and figures","volume":"14","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jagp.2019.09.009_bib0003","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jalz.2012.12.001","article-title":"Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future","volume":"9","author":"Geda","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jagp.2019.09.009_bib0004","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1517\/14656566.2015.1059422","article-title":"Advancements in the treatment of agitation in Alzheimer's disease","volume":"16","author":"Antonsdottir","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jagp.2019.09.009_bib0005","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.bp.114.148403","article-title":"Longitudinal course of behavioural and psychological symptoms of dementia: systematic review","volume":"209","author":"van der Linde","year":"2016","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jagp.2019.09.009_bib0006","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1017\/S1041610214002282","article-title":"The course of neuropsychiatric symptoms in community-dwelling patients with dementia: a systematic review","volume":"27","author":"Borsje","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.jagp.2019.09.009_bib0007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/1099-1166(200101)16:1<39::AID-GPS269>3.0.CO;2-F","article-title":"Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments","volume":"16","author":"Margallo-Lana","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2019.09.009_bib0008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1041610214001963","article-title":"Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition","volume":"27","author":"Cummings","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.jagp.2019.09.009_bib0009","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1532-5415.1986.tb04303.x","article-title":"Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated","volume":"34","author":"Cohen-Mansfield","year":"1986","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2019.09.009_bib0010","doi-asserted-by":"crossref","first-page":"M77","DOI":"10.1093\/geronj\/44.3.M77","article-title":"A description of agitation in a nursing home","volume":"44","author":"Cohen-Mansfield","year":"1989","journal-title":"J Gerontol"},{"issue":"Suppl 2","key":"10.1016\/j.jagp.2019.09.009_bib0011","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/00002093-199700112-00007","article-title":"Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory","volume":"11","author":"Koss","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.jagp.2019.09.009_bib0012","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/gps.930070706","article-title":"Reliability and validity of the Cohen-Mansfield Agitation Inventory in institutionalized elderly","volume":"7","author":"Finkel","year":"1992","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2019.09.009_bib0013","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1192\/bjpo.bp.117.005181","article-title":"Prevalence of and associations with agitation in residents with dementia living in care homes: MARQUE cross-sectional study","volume":"3","author":"Livingston","year":"2017","journal-title":"BJPsych Open"},{"key":"10.1016\/j.jagp.2019.09.009_bib0014","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2017.1307340","article-title":"An update on the advancements in the treatment of agitation in Alzheimer's disease","volume":"18","author":"Porsteinsson","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jagp.2019.09.009_bib0015","unstructured":"Janssen-Cilag Ltd: Risperdal film-coated tablets summary of product characteristics. 2018. https:\/\/www.medicines.org.uk\/emc\/product\/6856\/smpc. Accessed 18-Jul-19"},{"key":"10.1016\/j.jagp.2019.09.009_bib0016","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s40265-014-0293-6","article-title":"Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy?","volume":"74","author":"Gallagher","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jagp.2019.09.009_bib0017","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","article-title":"The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia","volume":"173","author":"Reus","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jagp.2019.09.009_bib0018","unstructured":"US Food and Drug Administration: Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. http:\/\/psychrights.org\/drugs\/FDAantipsychotics4elderlywarning.htm. Accessed 18-Jul-19"},{"key":"10.1016\/j.jagp.2019.09.009_bib0019","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.npp.1301492","article-title":"ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia","volume":"33","author":"Jeste","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jagp.2019.09.009_bib0020","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jagp.2019.09.009_bib0021","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials","volume":"14","author":"Schneider","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2019.09.009_bib0022","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jagp.2019.09.009_bib0023","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.schres.2016.04.012","article-title":"Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies","volume":"174","author":"Correll","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jagp.2019.09.009_bib0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2016.04.013","article-title":"Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia","volume":"174","author":"Kane","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jagp.2019.09.009_bib0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1573400512999160901094451","article-title":"Efficacy of adjunctive brexpiprazole in patients with major depressive disorder: a clinical overview","volume":"12","author":"Thase","year":"2016","journal-title":"Curr Psychiatry Rev"},{"key":"10.1016\/j.jagp.2019.09.009_bib0026","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/1573400512666160816095900","article-title":"Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment","volume":"12","author":"Nelson","year":"2016","journal-title":"Curr Psychiatry Rev"},{"key":"10.1016\/j.jagp.2019.09.009_bib0027","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/JCP.0000000000000665","article-title":"Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm","volume":"37","author":"Citrome","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jagp.2019.09.009_bib0028","doi-asserted-by":"crossref","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"Kales","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jagp.2019.09.009_bib0029","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis ofAlzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.jagp.2019.09.009_bib0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini\u2013mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jagp.2019.09.009_bib0031","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/gps.617","article-title":"Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version","volume":"17","author":"Iverson","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2019.09.009_bib0032","series-title":"Neuropsychiatric Inventory Nursing Home version (NPI-NH): Comprehensive Assessment of Psychopathology in Patients With Dementia Residing in Nursing Homes","author":"Cummings","year":"2009"},{"key":"10.1016\/j.jagp.2019.09.009_bib0033","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","article-title":"Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study","volume":"288","author":"Lyketsos","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jagp.2019.09.009_bib0034","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00019442-200111000-00004","article-title":"National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology","volume":"9","author":"Schneider","year":"2001","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2019.09.009_bib0035","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ana.410070516","article-title":"Pathological verification of ischemic score in differentiation of dementias","volume":"7","author":"Rosen","year":"1980","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jagp.2019.09.009_bib0036","series-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy","year":"1976"},{"key":"10.1016\/j.jagp.2019.09.009_bib0037","first-page":"26","article-title":"Sheehan Suicidality Tracking Scale (Sheehan-STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder","volume":"6","author":"Coric","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.jagp.2019.09.009_bib0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.jagp.2019.09.009_bib0039","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jagp.2019.09.009_bib0040","first-page":"105","article-title":"Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer's disease","volume":"2","author":"Allegri","year":"2006","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jagp.2019.09.009_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-007382","article-title":"Monetary costs of agitation in older adults with Alzheimer's disease in the UK: prospective cohort study","volume":"5","author":"Morris","year":"2015","journal-title":"BMJ Open"},{"issue":"12 Suppl","key":"10.1016\/j.jagp.2019.09.009_bib0042","first-page":"5","article-title":"American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition","volume":"164","author":"Rabins","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jagp.2019.09.009_bib0043","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.euroneuro.2017.01.002","article-title":"Benefits and harms of atypical antipsychotics for agitation in adults with dementia","volume":"27","author":"Farlow","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jagp.2019.09.009_bib0044","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamainternmed.2014.6930","article-title":"Falls and fractures with atypical antipsychotic medication use: a population-based cohort study","volume":"175","author":"Fraser","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jagp.2019.09.009_bib0045","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","article-title":"Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD","volume":"168","author":"Vigen","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jagp.2019.09.009_bib0046","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/0891988706298629","article-title":"Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances","volume":"20","author":"Lipkovich","year":"2007","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.jagp.2019.09.009_bib0047","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/alzrt86","article-title":"Globalization of Alzheimer's disease clinical trials","volume":"3","author":"Cummings","year":"2011","journal-title":"Alzheimers Res Ther"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748119305214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748119305214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:28:48Z","timestamp":1761020928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748119305214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1064748119305214"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2019.09.009","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736893597.793576061","asserted-by":"object"}]},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2019.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc. on behalf of American Association for Geriatric Psychiatry.","name":"copyright","label":"Copyright"}]}}